Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced the appointment of accomplished biotech and pharmaceutical executive, Olivia C. Ware to its Board of Directors.
“As we continue to grow and evolve our company strategy, it is critical that we expand the focus and expertise of our board. Olivia’s extensive background in drug portfolio and program management will be invaluable to the board and our organization. We welcome Olivia to the Revance team and look forward to working with her on our strategic growth initiatives for our aesthetics and therapeutics franchises,” said Mark J. Foley, President and Chief Executive Officer of Revance.
Ms. Ware brings over 20 years of experience in biotech and pharmaceutical drug development, commercialization and healthcare management, with a long track record of building and launching drugs, portfolio management, and directing programs at all phases of development. As a Senior Vice President at Principia Biopharma, Ms. Ware is the BTK Franchise Head and is also responsible for the Team Leadership and Portfolio Analytics functions. Prior, Ms. Ware led commercial, team leadership and product development at Genentech, and was integral to the launch of several of the world’s largest revenue generating drugs, including Rituxan®, Herceptin®, Avastin® and Lucentis®. In addition, Ms. Ware held leadership positions at Proteus Digital Health, CytRx and Baxter Healthcare Corporation. Her expertise also includes developing managed care, pricing and contracting strategy; developing marketing programs for field-based sales teams; and establishing, growing and optimizing organizations for long-term success.
Ms. Ware is President of Davidson College Board of Visitors and member of the Davidson Board of Trustees. She graduated from Davidson College and received her MBA from the University of North Carolina at Chapel Hill.
